Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 7 - The Untold Story

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.

Benzinga

Capricor Therapeutics (CAPR) Stock Is Sliding Today: Should Retail Investors Be Worried?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading lower Monday morning after the company reported new data from its exosome-based drug delivery platform. Here’s what investors need to know.

Benzinga

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

Report dashes hopes for new use for blockbuster weight-loss drug

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK plc (NYSE:GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ:ANAB) in the Delaware Chancery Court.

Benzinga

Treasurer blocks US takeover of Aussie pharma company

A takeover deal for an Australian pharmaceutical manufacturer has been knocked on the head, with the treasurer citing risks to the supply of critical medicines.

AAP

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

A short seller is challenging Praxis Precision Medicines Inc. (NASDAQ:PRAX) after the company claimed success from its Phase 3 trial of ulixacaltamide.

Benzinga

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts

Novartis AG (NYSE:NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

What's Driving InMed's (INM) 22% After-Hours Surge?

InMed Pharmaceuticals Inc. (NASDAQ:INM) shares rose 21.98% in after-hours trading Wednesday, reaching $1.50.

Benzinga

Why Is Agios Pharmaceuticals Stock Sinking Today?

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.

Benzinga

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report

A federal jury has convicted Ruthia He, the founder of the telehealth startup Done Global, for orchestrating a scheme that transformed the company into an unrestricted source for Adderall prescriptions. Prosecutors argued that this case highlighted serious abuses in online mental health care, as reported by the Wall Street Journal.

Benzinga

6 Healthcare Stocks With Strong Upward Momentum

Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.

Benzinga

CSL injects $2.3b into US for valuable blood plasma

After Donald Trump threatened pharmaceutical tariffs, CSL says it will invest another $2.3 billion building a new blood plasma facility in the United States.

AAP

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.

Benzinga

Judge to explain why he's approving Purdue Pharma settlement plan, which calls for $7B from Sacklers

A judge is set to explain why he's approving a plan for OxyContin maker Purdue Pharma to settle thousands of lawsuits over the toll of opioids

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

UK officials ‘working day and night’ to resolve NHS drug pricing row’

Patrick Vallance says government trying to rebuild relations with pharma industry as he outlines life sciences ambition

Benzinga

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ:RPTX).

Benzinga

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs

Eli Lilly And Co (NYSE:LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a pipeline that refuses to slow down, Lilly isn’t just lifting its own stock – it’s powering a growing…

The Guardian - US

Turmoil and tensions at FDA after dramatic exit of top drug regulator

Scramble to find replacement for George Tidmarsh shines light on dysfunction at US regulatory agency

Get all your
news in one place.

100's of premium titles.
One news app.

Axios

This new eye drop could help adults with age-related vision issues

The drops specifically combat presbyopia, an age related blurry vision issue.

The Independent UK

Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know

OxyContin maker Purdue Pharma's efforts to settle thousands of lawsuits over the toll of opioids is on the verge of approval

Benzinga

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight?

Cidara Therapeutics Inc. (NASDAQ:CDTX) shares are trending on Friday.

Benzinga

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

Dave Ricks, CEO of pharmaceutical giant Eli Lilly and Co. (NYSE:LLY), delivered a scathing critique of pharmacy benefit managers (PBMs), accusing the industry’s “middle actors” of “rent taking” and creating a “terrible incentive” structure that caused insulin list prices to skyrocket.

Benzinga

FDA Names Veteran Oncologist Richard Pazdur To Lead Drug Center After Ethics Scandal Ousts George Tidmarsh

The U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur as the new head of its drug center, succeeding Dr. George Tidmarsh, who was removed following an ethics complaint just months after his appointment.

Benzinga

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).

Benzinga

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.